What the research found

This is a business overview of startup costs for longevity medicine practices, not a clinical research finding. The piece breaks down four models for opening a practice in a major US metropolitan area: a lean virtual-only operation under $10,000; a multi-state virtual practice at $30–75k; a modest in-person clinic with exam rooms at $175–450k; and a comprehensive facility with on-site imaging and metabolic testing at $1–2.5 million.

The largest variable is real estate and build-out. Beyond day-one costs, the source highlights a commonly underestimated figure: the operating deficit during patient acquisition. At typical membership fees and growth rates, a practice burns through roughly $130,000 in overhead alone during the ramp-up phase (longer if you're drawing a salary), before revenue stabilizes.

The briefing also suggests cost-reduction strategies: starting virtual and adding physical space later, leasing or buying refurbished equipment rather than new, partnering with existing venues (clubs, gyms, health systems) to share space and patient flow, and narrowing focus to a single clinical niche.

Why it matters for you

If you're a MyKine user who works in medicine or is considering adding longevity services to your practice, this frames realistic entry points. Many clinicians assume they need a fully equipped clinic to compete; the source shows that virtual-first, data-driven practices using at-home lab kits and mobile phlebotomy are viable and significantly cheaper. You can validate the model and build a roster before committing $200k+ to a lease and equipment.

The operational ramp is the real shock. Your monthly overhead doesn't pause while you recruit patients. If you're planning to add a longevity service line within an existing practice or health system, you already have some of this infrastructure (space, staff, existing patient base), which dramatically shortens the payoff timeline. For solo practitioners, the lean start model suggests you can test longevity programming while maintaining other clinical work, then scale once members are reliably paying.

For biomarker and protocol tracking, this also implies that your data collection method matters less than consistency. At-home kits and remote assessment tools are now standard in many practices, which means the friction for patients entering a longitudinal tracking program is lower than ever.

Caveats

• Business intelligence, not clinical evidence. This is practitioner advice about practice economics, not a study of patient outcomes or protocol efficacy.
• Regional variation. Figures are anchored to major US metros; rural, suburban, and international costs differ materially.
• Planning estimates only. Actual costs will vary by location, equipment brand, lease negotiation, and build-out complexity. The source explicitly advises getting real quotes before committing.
• No comparison of patient retention or revenue by model. The piece assumes membership models and steady growth but doesn't show which architecture produces the strongest long-term margins or patient satisfaction.